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Abstract. The use of 5α-reductase inhibitors (5α-RIs) as pros-
tate cancer chemoprevention agents is controversial. Two large 
randomized trials, the Prostate Cancer Prevention Trial (PCPT) 
and the Reduction by Dutasteride of Prostate Cancer Events 
(REDUCE) Trial, have both shown a decreased incidence of 
prostate cancer in patients administered with 5α-RIs. Both 
studies showed, however, an increased risk of higher-grade 
prostate cancer. Numerous studies have since analyzed the 
inherent biases in these landmark studies and have used math-
ematical modeling to estimate the true incidence of prostate 
cancer and the risk for high-grade prostate cancer in patients 
undergoing 5α-RI treatment. All primary publications asso-
ciated with the PCPT and REDUCE studies were reviewed 
in detail. Pertinent references from the above publications 
were assessed and a literature search of all published articles 
associated with PCPT, REDUCE or 5α-RIs as chemopre-
ventative agents through October 2013 was performed using 
Pubmed/Medline. PCPT and REDUCE both showed a signifi-
cant decrease in the incidence of prostate cancer following the 
administration of 5α-reductase inhibitor, as compared with 
placebo, suggesting that 5α-RIs may be effective agents for 
prostate cancer chemoprevention. Inherent biases in the design 
of these two studies may have caused an artificial increase 
in the number of high-grade cancers reported. Mathematical 
models, that integrated data from these trials, revealed neither 
an increased nor decreased risk of high-grade disease when 
taking these biases into consideration. Moderately strong 
evidence exists that 5α-RIs may reduce the risk of prostate 
cancer. PCPT and REDUCE showed a decreased prevalence 
of prostate cancer in patients taking 5α-RIs. Urologists should 
have a working knowledge of these studies and discuss with 
patients the risks and benefits of 5α-RI treatment. Further 
studies to evaluate the cost-effectiveness of chemoprevention 
with 5α-RIs and appropriate patient selection are warranted.
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1. Introduction
Prostate cancer is the second most common cancer among men, 
with 206,640 diagnoses and 28,088 prostate cancer-associated 
deaths reported in 2009 (1). The decreased mortality rate of 
prostate cancer in the prostate‑specific antigen test (PSA) era 
is well-documented (2). This is widely credited due to the 
possibility for earlier diagnosis of the disease, which enables 
treatment while the cancer remains localized in the prostate. 
With an increased rate in diagnoses of prostate cancer came 
concerns of over‑treatment of clinically insignificant tumors 
and significant treatment side effects that have put prostate 
cancer into the national public health spotlight (3). These 
concerns culminated in May 2012 when the United States 
Preventative Task Force recommended against the use of PSA 
as a screening test for prostate cancer (3).
Prostate cancer has been considered to be an ideal tumor 
for chemoprevention due to its multi-step molecular pathway, 
prolonged latent phase and increased incidence with age (4). 
Several trials have pursued agents that could decrease the 
incidence and/or progression of prostate cancer (4). The 
Selenium and Vitamin E Cancer Prevention Trial investigated 
the impact of vitamin E and selenium alone and in combina-
tion on prostate cancer, and produced unexpected negative 
results. There was a reported increase in prostate cancer 
incidence in the group receiving vitamin E, while no signifi-
cant effect was detected in the other groups (5). Recognizing 
the tumor-enhancing effects of an agent that was previously 
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reported by a wealth of experimental basic findings as being 
chemopreventive, severely challenged the translational signifi-
cance in a clinical setting (6). The Alpha-Tocopherol, Beta 
Carotene Prevention Trial showed initial promising results for 
prostate cancer prevention, but these results did not generate 
significance as the study progressed (7). Murine studies of the 
selective estrogen receptor modulator toremifene revealed its 
potential for delaying prostate cancer progression, but studies 
in human subjects have failed to deliver positive results (8). 
Other common medications, such as statins and nonsteroidal 
anti‑inflammatory drugs, have also been evaluated in numerous 
studies with controversial results (6,-12).
5α-reductase inhibitors (5α-RIs) have been among the most 
controversial candidates in the search for chemopreventative 
agents for prostate cancer; 5α-reductase converts testosterone to 
the intracellular active dihydrotestosterone, with a high affinity 
for the androgen receptor (13). Inhibitors of 5α-reductase 
activity are clinically used in the treatment of benign prostatic 
hyperplasia, through their ability to decrease the volume of 
the prostate gland in aging men. There are two isoenzymes of 
5α-reductase: Type 1, which is expressed in the liver and skin, 
and type 2 that is expressed in the prostate (14). Finasteride 
(Proscar®) inhibits only the type 2 isoenzyme, but dutasteride 
(Avodart®) inhibits both the type 1 and type 2 isoenzymes. 
While the fundamentally significant contribution of androgens 
to prostate cancer etiology and progression had long been the 
focus of intense molecular exploitation, there had been no 
clinical trial to investigate the role and effects of 5α-reductase in 
prostate cancer in humans (15). The PCPT and REDUCE trials 
were designed to investigate the effect of finasteride (PCPT) 
and dutasteride (REDUCE) on the incidence of prostate cancer. 
Despite polarizing designs and differences in the composition 
of patient populations enrolled in the studies, the overall results 
and conclusions were analogous, simultaneously raising hope 
and concern for the use of 5α-RIs in the treatment of prostate 
cancer. This review aims to evaluate these two landmark clinical 
trials within the framework of the current debate, and reviews 
pertinent studies regarding the use of targeting of 5α-reductase 
for prostate cancer chemoprevention through October 2013.
2. Trials of prevention, PCPT vs. REDUCE: Prostate can-
cer finds its ‘groove’
Data from the PCPT were published in July 2003 in the New 
England Journal of Medicine (16). This study tested whether 
lowering circulating androgen levels in the prostate could 
reduce the risk of developing prostate cancer. Inclusion criteria 
were males aged ≥55 years old with PSA levels ≤3.0 ng/ml and 
a normal digital rectal examination (DRE) result. Patients who 
were randomized had annual PSA/DRE tests, semi-annual 
clinic visits and quarterly telephone follow-up calls. A prostate 
biopsy was recommended for those exhibiting a PSA >4.0 ng/ml 
or abnormal DRE, and the majority of biopsies performed were 
6-core biopsies. An adjustment factor of 2.3 was applied to the 
treatment arm to account for the biological impact of finasteride 
on lowering the serum PSA values, and to maintain an equivalent 
number of biopsies in the placebo group. The study, originally 
planned for a 7-year duration, was terminated 15 months early 
due to meeting the objectives of the study ahead of schedule. A 
significant decrease in the prevalence of prostate cancer in the 
finasteride‑treated group, as compared with the placebo group 
(18.4 vs 24.4%, P≤0.001), was observed. The impact of these 
data was reduced due to the observations that of the patients 
diagnosed with prostate cancer, an increased number of patients 
were found to have high-grade tumors (Gleason 7-10) in the 
finasteride-treatment group, as compared with the placebo 
group (37 and 22% respectively, P<0.001). Subsequently, this 
led to speculation among patients, urologists, epidemiologists 
and health policy makers as to whether or not finasteride, 
previously presented as an attractive chemoprevention agent for 
prostate cancer, was predisposing patients to a more aggressive 
disease, thus compromising treatment outcomes upon prostate 
cancer diagnosis. 
The REDUCE trial was designed to recruit men at an 
increased risk for prostate cancer with no evidence of the 
disease at baseline (17). Initial results of the REDUCE trial 
were published in the New England Journal of Medicine in 
April 2010 with great anticipation of the radical effect on 
blocking 5α-reductase action upon the initiation of malignant 
prostate growth (18). The study was planned for 4 years of 
follow-up, and protocol biopsies were planned at 2 and 4 years 
in efforts to minimize the ‘for cause’ biopsies. These biopsies 
were performed at the discretion of the clinician, likely based 
on elevated PSA levels or an abnormal DRE, but this was not 
explicitly defined in the study. The biopsies were obtained on an 
as-needed basis, between the 2 and 4 year scheduled biopsies. 
Biopsies were to be 10 cores to balance between the need to 
maximize the detection of clinically significant tumors, yet 
minimize the over-diagnosis of low grade tumors (17).
The primary endpoint of this study was the diagnosis 
of prostate cancer by a TRUS biopsy during the study. This 
endpoint was examined in several subgroups: Age, family 
history of prostate cancer, International Prostate Symptom 
Score, prostate volume, PSA level and body mass index. The 
incidence of prostate cancer was lower in the dutasteride 
arm in every subgroup. During the 4-year period of the trial, 
prostate cancer was diagnosed in 659 (19.9%) patients of the 
3,305 patients in the dutasteride arm of the study and 858 
(25.1%) of the 3,424 patients in the placebo arm, resulting in 
an absolute risk reduction of 5.1% and a relative risk reduction 
of 22.8%. The majority of tumors were low grade, with 70% 
of the total number of cancers exhibiting a Gleason score of 5 
or 6. The number of tumors with Gleason grades of 7-10 did 
not differ significantly over the course of the 4-year study, or 
within the subgroup of biopsies taken at the 1- to 2- or 3- to 
4-year point. The promise of an absence of a higher number 
of tumors with Gleason grade 8-10 at the end of 1-2 years in 
the dutasteride group, was counteracted by a significant differ-
ence detected in the number of tumors with Gleason grade 8-10 
in the later follow-up (years 3-4) (12 and 1, dutasteride vs. the 
placebo group, respectively, P<0.003). This last finding from the 
REDUCE trial likely precipitated the denial by the Food and 
Drug Administration for the use of 5α-RIs as prostate cancer 
chemopreventative agents, serving to reiterate the controversial 
and apparently analogous results from the PCPT.
3. Discussion
The results of PCPT and REDUCE showed a significant 
reduction in the overall incidence of prostate cancer in patients 
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administered with 5α-RIs, but there was an increased incidence 
of high grade tumors in the treatment arm of both studies. 
Numerous reports have aimed to dissect these two studies and 
debate whether or not the results reflect a true increase in inci-
dence of high-grade tumors or if this is merely the result of an 
inherent bias within the studies. Debates have revolved around 
the number of patients excluded from the final analysis of the 
PCPT, increased sensitivity and specificity of prostate cancer 
detection in biopsies on patients in the treatment arms of each 
study and inherent selection biases in both studies.
The fact that a large number of patients in the PCPT were 
not included in the final analysis for various reasons requires 
serious consideration. In the finasteride group, 3,290/8,137 
(46.3%) patients were not included in the final analysis due to 
death (7.0%), declining end of study biopsy (25.4%), being lost 
to follow‑up (8.0%) or being excluded from the final analysis 
(5.8%). A similar number of patients were not included in the 
placebo group, with 3,016/8,158 (42.4%) patients excluded 
due to death (6.7%), declining end of study biopsy (22.8%), 
being lost to follow‑up (7.4%) or being excluded from the final 
analysis (5.5%). Unanswered questions remain, with >40% of 
the data in each group not being included in the final analysis. 
Redman et al (19) created a statistical model to account 
for the large number of PCPT patients that did not have an 
endpoint (19). Covariates, such age, family history and treat-
ment arm assignment were used to predict the outcomes of 
these patients (lacking reported outcomes), and such analysis 
revealed that prostate cancer prevalence remained significantly 
lower in the finasteride group as compared with the placebo 
(14.7 vs 21.1%, P<0.0001). There was no significant increase, 
however, in the high‑grade cancer detected in the finasteride 
group as compared with the placebo (4.8 vs 4.2%, P=0.012). 
Another potential bias in these studies is the increased sensi-
tivity and specificity of the prostate biopsy in the treatment arms 
of each study. 5α-RIs are known to decrease prostate volume (20) 
and outcomes of the REDUCE trial documented a significant 
reduction in the prostate volume in the treatment arms as 
compared with controls, with the prostate volume in the placebo 
group of the REDUCE trial increasing from a mean of 45.8 ml 
at baseline to 52.3 and 56.2 ml at 2 and 4 years, respectively. The 
dutasteride group decreased from 45.7 to 38.6 ml, from baseline 
to 2 years, and remained stable at 39.0 ml at the 4-year mark as 
expected. Pinsky et al (21) aimed to estimate how this difference 
in volume would impact the sensitivity and specificity of pros-
tate biopsy. Towards resolving this issue, a model was created to 
extrapolate the pathological findings from radical prostatectomy 
specimens and their correlation with biopsy specimens, to those 
who did not undergo a prostatectomy, but had been diagnosed 
with prostate cancer on biopsy. The misclassification rate (the 
rate of tumors that were low-grade on biopsy but high-grade 
on prostatectomy specimen) was significantly lower in the 
finasteride arm (34.6%) as compared with the placebo (52.6%). 
Given the low overall number of high-grade tumors, this could 
be underlying the observed increased sensitivity for detecting 
high‑grade disease on biopsy in the finasteride arm and a false 
increase in true high‑grade cancers in the finasteride group.
Cohen et al (22) also investigated the effect of prostate 
volume on high-grade disease detection. Development of a 
logistic regression model based on prostate volume as well 
as race, family history, age and number of biopsy cores, 
indicated that the association of gland volume and detection 
of high-grade cancer existed independently of the drug effect. 
A second model designed to predict an odds ratio for low- and 
high-grade disease, revealed no difference in the high-grade 
disease between the finasteride and placebo groups after 
volume adjustment. Similarly, Kaplan et al (23) created a 
logistic regression model that adjusted the results based on the 
sampling density of biopsies in the PCPT. They showed that 
finasteride significantly reduced the risk of prostate cancer rela-
tive to the placebo, across multiple groups of prostate cancer 
(Gl 4‑7), with no significant effect on Gl 2‑3 or 8‑10 prostate 
cancer groups (23). Another model integrating the varying 
sensitivity of prostate biopsies and its potential effect on pros-
tate cancer detection (19), revealed a risk of high-grade disease 
either equivalent to or less than the placebo in the finasteride 
arm. Biopsy sensitivity was shown to have to be >85% in the 
placebo group and 25‑30% in the finasteride group for there to 
be a significant increase in high‑grade disease in the finasteride 
group, based on these models. This combination seems highly 
unlikely given that finasteride can increase the sensitivity 
for detection of high-grade tumors. This evidence implicates 
inherent biases in the PCPT trial design being responsible for 
the observed increase in high-grade tumors in the treatment 
arm, thus specifically illustrating how small changes in biopsy 
sensitivity could explain observed increased risk of high-grade 
prostate cancer. 
Recognition of the role of selection bias in the PCPT trial 
undermining the selection of patients for prostate biopsy may 
provide a constructive platform. Despite the attempt to have an 
even number of biopsies in each group by adjusting the PSA in 
the treatment arm by 2.3 (vs. 2), recommendations for biopsy 
were higher in the placebo group (24.8%) as compared with 
finasteride treatment (22.5%). A significantly lower number 
of men (P<0.001) underwent a biopsy for elevated PSA in 
the finasteride group (48.4%) as compared with the placebo 
(56.5%). This investigator-generated bias could distinctly 
impact the PCTP outcome on two tiers. Firstly, the correc-
tional factor of 2.3 may have led to a disproportionate decrease 
in the number of biopsy recommendations in the finasteride 
treatment group and delayed the diagnosis of prostate cancer. 
Secondly, an increased proportion of biopsies, prompted by 
an abnormal digital rectal examination, may have led to an 
increased number of diagnoses of high-grade cancers as previ-
ously established (24). In retrospect, it may have been more 
useful to use the correction factor of 2 for serum PSA levels in 
the finasteride‑treated patients. This would have more closely 
simulated clinical practice while potentially avoiding the 
aforementioned selection biases.
There was potential selection bias in the REDUCE trial. 
A higher number of patients were diagnosed with prostate 
cancer at the 1-2 year mark in the placebo group and were 
therefore removed from the study. A proportion of these 
patients with initial low-grade (Gl 5-6) tumors may have 
progressed to higher grade (Gl 7-10) if left in the study 
and re-biopsied. One smaller study showed a significant 
number of tumors that increased in grade over a similar time 
interval (25). Should these results provide a direct transla-
tion into the REDUCE trial, it is unlikely that a significant 
increase in the number of high-grade tumors would have 
been found in the treatment arm.
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Both PCPT and REDUCE used prostate cancer incidence 
as a primary endpoint. One recent study used data from the 
Prostate, Lung, Colorectal and Ovarian trial to predict prostate 
cancer mortality using prostate cancer incidence data from 
the PCPT and REDUCE trials (26). Prognostic data, such 
as Gleason score, PSA and clinical staging from each study 
were used, as were aforementioned adjusted results from 
PCPT based on increased sensitivity of prostate biopsy from 
a decreased prostate volume. These results showed no signifi-
cant differences in prostate cancer mortality in these studies, 
with a trend towards an increased risk using the original PCPT 
date, and a trend towards decreased risk using the adjusted 
PCPT and REDUCE data. These data were corroborated by 
a more recent updated analysis of patients from the PCPT, 
which showed no significant differences in overall survival 
between the placebo and treatment groups (27).
Perhaps the most compelling evidence that the observed 
increased incidence of high-grade prostate cancer is unreal-
istic stems from a study estimating the number of high-grade 
tumors if all the patients with a positive biopsy had undergone 
a prostatectomy (19). Data from 500 patients who underwent 
a prostatectomy of the 2,017 patients diagnosed with prostate 
cancer in PCPT were analyzed, towards a model develop-
ment to evaluate factors increasing the odds of undergoing 
a prostatectomy and subsequent risk of these patients having 
high-grade disease. Issues of selection bias become quickly 
apparent, as noted by the authors; the patients who underwent a 
prostatectomy were not a random sample. A younger age, PSA 
at randomization and biopsy prompted by PSA or DRE were 
all positive predictors of a prostatectomy. These patients were 
also more likely to be diagnosed with prostate cancer on ‘for 
cause’ biopsies with a longer time observed after diagnosis. 
Upon factoring in this bias, the adjusted results of the PCPT 
are encouraging. The estimation of prostate cancer prevalence 
showed a decreased risk of overall and high-grade disease in 
the finasteride arm as compared with the placebo, resulting 
in a 27% relative risk reduction for high-grade tumors (95% 
confidence interval, 0.56‑0.96; P=0.02) (19).
4. Future REDEEM-ing of 5α-reductase inhibition 
It is important to determine where these discussed consider-
ations may lead. Both the PCPT and REDUCE trials unfolded 
a provocative data in the analysis of prostate cancer chemo-
preventative strategies. Table I summarizes key similarities 
and differences between the two trials. The PCPT was a larger 
study that was comprised of patients with much lower baseline 
PSA and normal DRE, and no previous biopsies. The results 
revealed a decreased number of patients diagnosed with pros-
tate cancer in the finasteride group. Of those patients, however, 
there was a significant increase in the number of higher‑grade 
tumors as compared with the placebo. The REDUCE trial was 
designed to evaluate patients with an increased risk of prostate 
cancer, based on elevated PSA, and with recent prior negative 
prostate biopsy. The majority of biopsies (93%) were scheduled 
accordingly to eliminate clinician-generated biases, based on 
rectal examination and PSA. Mirroring the outcomes of the 
PCPT trial, REDUCE also revealed a significant decrease 
in prostate cancer incidence in the treatment arm, and an 
increased number of high-grade tumors following treatment. 
The significant decrease in prostate cancer prevalence in 
both the PCPT and REDUCE trials raises hope for potential 
Table I. Design comparison of the PCPT and the REDUCE trial.
 PCPT REDUCE
Publication date 7/2003 4/2010
Designed length of study (years) 7 4
5α-reductase inhibitor Finasteride (Proscar) Dutasteride (Avodart)
Cancer risk in cohort Low risk Higher risk
 (PSA <3, normal DRE) (PSA 2.5-10)
Biopsy prior to study No Yes
Number enrolled 24,482 8,231
Number randomized 18,882 8,122
Number in final analysis    9060 6,706
PSA correction factor 2.3   2
Decision for biopsy PSA >4, abnormal DRE Protocol at 2 and 4 years
 and at end of study
Median number of biopsy cores 6 10
Overall incidence of prostate cancer (%) 21.5 22.5
Overall relative risk reduction (%) 24.8 22.8
Concern for increased risk of HG tumors 6.4% of patients with Gl 7-10 in 12 Gl 8-10 tumors in treatment arm in
 treatment arm compared to 5.1%  years 3-4 compared to only 1 in placebo 
 in placebo arm arm in years 3-4
PCPT, Prostate Cancer Prevention Trial; REDUCE, Reduction by Dutasteride of Prostate Cancer Events Trial; PSA, prostate‑specific antigen; 
DRE, digital rectal examination; HG, high grade; Gl, Gleason score.
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chemoprevention agents in the fight against prostate cancer. 
This emerges as an increasingly important argument with the 
changing landscape of medicine and the intense scrutiny over 
the diagnosis and treatment of prostate cancer. The acceptance 
for the use of 5α-RIs in prostate cancer chemoprevention is 
the notion of their potential effect in predisposing patients 
to high-grade prostate cancer. This is an unfortunate conse-
quence from the over‑interpretation of findings from the PCPT 
and REDUCE trials. Numerous mathematical models reflect 
with confidence that 5α-RIs are not likely to increase risk for 
high‑grade prostate cancer, and significantly enough others 
predict an actual reduced risk for all grades of prostate cancer 
by these agents (19,21-23). Furthermore, follow-up data from 
the REDUCE trial following an additional 2 years, showed no 
new Gleason 8-10 tumors (28). Despite the strong collective 
evidence towards a chemoprevention action that can be clini-
cally exploited, support has not been sufficiently powerful for 
the Food and Drug Administration's Oncologic Drug Advisory 
Committee to approve the use of 5α-RIs for prostate cancer 
chemoprevention (29).
Besides the potential for chemoprevention, the therapeutic 
value of 5α-RIs has also been interrogated in the treatment of 
prostate cancer during the progression to an advanced disease. 
The REDEEM trial revealed great promise that dutasteride 
may decrease the progression of low-grade prostate cancer in 
men undergoing active surveillance (30). Additional ongoing 
trials are pursuing the potential therapeutic value of 5α-RIs 
in patients facing biochemical failure following definitive 
therapy and adjuvant therapy with bicalutamide in castra-
tion-resistant prostate cancer. One could easily argue that 
there is a subset of patients who would benefit from 5α-RI 
treatment, depending on the cellular landscape of individual 
tumors, but this subset requires stringent profiling, without 
factoring in cost-effectiveness. Kattan et al (31) reported that 
dutasteride may be cost-effective as a chemoprevention agent, 
but only in patients at high-risk for prostate cancer diagnosis. 
Reports by an independent investigative team, however, 
sharply challenged the cost‑effectiveness of finasteride, based 
on survival and quality of life as outcomes of success (32). 
As controversy still surrounds the value of the 5α-RIs in 
impairing prostate cancer, additional studies are warranted to 
determine a safe, efficacious, cost‑effective chemopreventive 
agent to be given to young men, for preventing the disease in 
the ageing population. The non-biased counseling of patients 
on the risks and benefits associated with the 5α-reductase 
inhibitors and their potential for chemoprevention of prostate 
cancer is built on the clinical impact of the two trials, PCTP 
and REDUCE. 
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